|
- Treatment Clinical Trials for Small Cell Lung Cancer
NCI supports clinical trials studying new and more effective ways to detect and treat cancer Find treatment clinical trials for small cell lung cancer
- Small Cell Lung Cancer Clinical Trials - Mayo Clinic Research
This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy in treating patients with breast cancer, non-small cell lung cancer, or prostate cancer that has spread to other parts of the body
- Treatments in Clinical Trials for Small Cell Lung Cancer - Healthline
Researchers are hopeful that new treatments for small cell lung cancer will help improve survival rates Learn about these new potential treatments
- Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Durvalumab in Limited-Stage Small-Cell Lung Cancer Results A total of 264 patients were assigned to the durvalumab group, 200 to the durvalumab–tremelimumab group, and 266 to the placebo group
- Clinical Trials
Clinical Trials A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), Versus Treatment of Physician’s Choice (TPC) in Subjects with Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)
- Lung Cancer Research - MD Anderson Cancer Center
As one of the world's largest cancer research centers, MD Anderson is leading the investigation into new methods of lung cancer diagnosis and treatment Each patient benefits from the most advanced research, delivered as rapidly as possible Our current lung cancer research efforts include: Using stereotactic radiosurgery to treat brain metastases of small cell lung cancer Integrating new
- Thoracic (Lung) Cancer Clinical Trials and Research
Doctors in our Lowe Center are also researching lung cancer in non-smokers, small cell lung cancer, resistance to targeted therapies, familial lung cancer, and other related areas
- What’s On the Horizon for Small Cell Lung Cancer Research?
As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung cancer research This optimism comes in the wake of the Food and Drug Administration’s (FDA’s) approval of Imdelltra (tarlatamab-dlle) in May 2024 for the treatment of patients with extensive-stage small cell lung cancer (SCLC)
|
|
|